# NEBIDO in Symptomatic Late Onset Hypogonadism (SLOH)

> **NCT01092858** · PHASE4 · TERMINATED · sponsor: **Bayer** · enrollment: 4 (actual)

## Conditions studied

- Hypogonadism

## Interventions

- **DRUG:** Testosterone Undeconate (Nebido, BAY86-5037)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01092858
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-09
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2014-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01092858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01092858, "NEBIDO in Symptomatic Late Onset Hypogonadism (SLOH)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01092858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*